On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE:NVS) Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary ...

Novartis wins FDA approval for the label expansion of Fabhalta for a third indication - treatment of adults with C3 glomerulopathy.

Novartis said it received accelerated approval from the U.S. Food and Drug Administration for a treatment to bring down elevated levels of protein in the urine of adults who have a rare kidney ...

The U.S. Food and Drug Administration (FDA) on Wednesday granted accelerated approval for Novartis AG’s (NYSE:NVS) Vanrafia (atrasentan) to reduce proteinuria in adults with primary ...

Novartis strengthens its renal disease portfolio with accelerated approval of another drug for immunoglobulin A nephropathy.

The Food and Drug Administration approved Ozempic for treating patients with chronic kidney disease on Tuesday, marking the latest authorized use for Novo Nordisk’s popular drug known for ...

The Food and Drug Administration approved Ozempic for treating patients with chronic kidney disease on Tuesday, marking the latest authorized use for Novo Nordisk’s popular drug known for ...

Novartis' Fabhalta (iptacopan) receives FDA accelerated approval as a first-in-class complement inhibitor for IgA nephropathy, reducing proteinuria in adults at risk of rapid disease progression ...

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory reviews continue.